Verdiva Bio, one of the best funded private companies in obesity, has terminated a mid stage trial of its oral GLP-1 pill, Endpoints News reported on October 13, with the company citing the evolution of the market rather than a safety signal or a failed readout. No company release accompanied the report, and the reporting available to this edition does not publicly identify which registered study was stopped, so the specific program claim is carried at grade C.
What is on the record about Verdiva’s mid stage work is its own disclosure. Its lead candidate, VRB-101, is a once weekly oral, cAMP biased GLP-1 peptide analog. The Phase 2b EVOLVE-2 study completed enrollment in February 2026 with more than 200 participants across 22 US sites, five active arms and one placebo arm, dosed for 20 weeks, with mean percentage change in body weight as the primary endpoint and topline data expected by the end of 2026. The company also has VRB-103, an oral amylin analog in Phase 1, which it presented preclinical data on in late September.
The commercial logic is visible even without the company’s explanation. Oral Wegovy was approved in December 2025, Lilly’s oral program is advancing, and more than 700 obesity trials are running worldwide, in Verdiva’s own president of research and development’s count. A once weekly oral peptide that looked differentiated in 2024 competes in 2026 against daily pills already on the market and against combination and amylin programs with large company backing.
Whether the termination is a portfolio refocus toward the amylin program or a broader retreat will only be clear when Verdiva next discloses, or when the trial registry is updated. This edition will update the story in place when the registry or the company confirms which study closed.